Search clinical trials for: Icotinib Hydrochloride

Total 9573 results

Azienda Ospedaliera Universitaria Integrata Verona
University of Milan

Unknown

Prasugrel in Severe COVID-19 Pneumonia (PARTISAN)

Thrombosis | COVID19

Italy
Qilu Hospital of Shandong University

Unknown

Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer (TCL-1)

Non-Small-Cell Lung Cancer

China
Samyang Biopharmaceuticals Corporation
Severance Hospital

Completed

Crossover Study to Compare Pharmacokinetic Property of SYO-1126 and Glivec Film Coated Tab in Healthy Male Volunteers

Healthy

Korea, Republic of
Telik

Terminated

Study of (Telintra®) in Non-Del(5q) Myelodysplastic Syndrome

Myelodysplastic Syndrome (MDS)

United States
Jan Beumer
Novartis Pharmaceuticals

Completed

Effect of Calcium on Tasigna Pharmacokinetics (PK) in Healthy Volunteers

Healthy

United States
Betta Pharmaceuticals Co., Ltd.

Unknown

Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKI

Non-small Cell Lung Cancer

China
M.D. Anderson Cancer Center

Completed

Study of Lonafarnib and Gleevec in Chronic Myelogenous Leukemia

Chronic Myelogenous Leukemia

United States
Qianfoshan Hospital

Not yet recruiting

Hydromorphone for Perioperative Analgesia in Lung Tumor Ablation Parallel Controlled

Pulmonary Nodule | Ablation
University Hospital, Bordeaux

Completed

Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2) (NiloPost-STIM)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

France
Seoul National University Hospital

Completed

Effect of Nilotinib in Cerebellar Ataxia Patients

Ataxia, Cerebellar | Ataxia, Progressive

Korea, Republic of
Novartis Pharmaceuticals

Completed

A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies

Hypereosinophilic Syndrome | Chronic Myelogenous Leukemia | Systemic Mastocytosis | Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)

United States, Poland, Italy, Belgium, Canada, France, Australia, Netherlands, Sweden, Switzerland, United Kingdom, Spain, Korea, Republic of, Austria, Germany, Denmark, Finland, Singapore, Taiwan, Hong Kong, New Zealand, Norway
Asan Medical Center

Completed

Nilotinib Pharmacokinetics (PK) in Gastrointestinal Stromal Tumor (GIST): Nilotinib PK

Gastrointestinal Stromal Tumors

Korea, Republic of
Novartis Pharmaceuticals

Terminated

Trial to Evaluate the Improvement of Chronic Low-grade AEs in Patients With Ph+ CML With Optimal Response to Imatinib When Switched to Nilotinib (MACS1532)

Philadelphia Positive (Ph+) Chronic Myeloid Leukemia

Russian Federation
Novartis Pharmaceuticals

Completed

Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST)

Gastrointestinal Stromal Tumor

Turkey
Novartis Pharmaceuticals

Completed

Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase (MACS0439)

Chronic Myeloid Leukemia

Brazil
Samsung Medical Center

Unknown

Multicenter, PhaseⅣ, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to Dasatinib

Leukemia, Chronic Myeloid
Andrew Sloan, MD

Completed

Imaging Procedure Using ALA in Finding Residual Tumor in Grade IV Malignant Astrocytoma

Brain and Central Nervous System Tumors

United States
Aptabio Therapeutics, Inc.

Recruiting

Study of APX-115 in Contrast Induced Acute Kidney Injury in Subjects Undergoing PCI

Contrast Induced Acute Kidney Injury

Korea, Republic of, United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Hormone Therapy in Treating Women With Breast Cancer

Breast Cancer

United States
European LeukemiaNet
Ludwig-Maximilians - University of Munich; Heidelberg University

Active, not recruiting

2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patients (NAUT)

Chronic Myeloid Leukemia

Germany, Netherlands
Novartis Pharmaceuticals

Completed

Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment

Gastrointestinal Stromal Tumors

Japan
M.D. Anderson Cancer Center
Array BioPharma

Terminated

An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)

Leukemia

United States
Novartis Pharmaceuticals

Completed

A Study of Nilotinib in Adult Patients With Imatinib Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase (ENACT)

Chronic Myeloid Leukemia

Colombia, Venezuela
Novartis Pharmaceuticals

No longer available

Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or Intolerant

Chronic Myelogenous Leukemia

Canada
Novartis Pharmaceuticals

Completed

Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors (GIST) and Are Resistant to Imatinib Mesylate (Radix)

Progressive Gastrointestinal Stromal Tumor

Germany
Northwestern University
University of Iowa; University of Rochester; Michael J. Fox Foundation for Parkinson...

Completed

Nilotinib in Parkinson's Disease (NILO-PD)

Parkinson Disease

United States
Stanford University

Completed

Imatinib in Systemic Sclerosis

Scleroderma, Systemic

United States
Heidelberg University
Novartis

Completed

Study to Evaluate Imatinib in Desmoid Tumors

Desmoid Tumor | Aggressive Fibromatosis

Germany
Novartis Pharmaceuticals

Completed

Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases

Life Threatening Diseases
UNICANCER

Completed

Imatinib Mesylate in Treating Patients With Recurrent or Refractory Fibromatosis

Desmoid Tumor

France
University of Michigan Rogel Cancer Center

Terminated

Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma

Thyroid Cancer

United States
University Hospital, Bordeaux

Completed

Evaluation of the Persistence of the Complete Molecular Remission After Stopping Imatinib Chronic Myeloid Leukemia (STIM)

Myeloid Leukemia, Chronic

France
University Hospital, Bordeaux
Novartis; Ministry of Health, France

Completed

Efficacy and Safety of Imatinib in Scleroderma (SCLEROGLIVEC)

Scleroderma, Systemic | Scleroderma, Localized

France
Maisonneuve-Rosemont Hospital
Hippocrate Research & Development

Unknown

Gleevec Administered Preoperatively to Reduce Gastrointestinal Stromal Tumor (GIST)

Gastrointestinal Stromal Tumors

Canada
University of Arizona
National Cancer Institute (NCI)

Recruiting

Metformin for the Prevention of Oral Cancer in Patients With Oral Leukoplakia or Erythroplakia

Oral Leukoplakia | Erythroplakia

United States, Canada
National Cancer Institute (NCI)

Recruiting

Metformin for Chemoprevention of Lung Cancer in Overweight or Obese Individuals at High Risk for Lung Cancer

Lung Carcinoma

United States, Canada
Luye Pharma Group Ltd.

Not yet recruiting

To Evaluate the Long-term Efficacy and Safety of Toludevenlafaxine Hydrochloride Sustained-release Tablets

Major Depressive Disorder
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Recruiting

Study of ZG0895.HCl in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Tang Yida
Chinese Society of Cardiology

Not yet recruiting

Cardiovascular Diseases and Diabetes Prevention Programme in Metabolic Syndrome (CDPP) (CDPP)

Metabolic Syndrome

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast Cancer

HER2-negative Breast Cancer

China
National Cancer Institute (NCI)

Active, not recruiting

Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
Eli Lilly and Company

Completed

Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Recurrent, Advanced, or Metastatic Endometrial Cancer

Endometrial Cancer

United States
Eli Lilly and Company

Completed

Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Metastatic Refractory Ovarian Cancer or Primary Peritoneal Cancer

Ovarian Cancer | Primary Peritoneal Cavity Cancer

United States
University Health Network, Toronto
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Salivary Gland Cancer

Head and Neck Cancer

United States, Canada
University Hospital, Bordeaux

Completed

Multicenter Trial Estimating the Persistence of Molecular Remission in Chronic Myeloid Leukaemia in Long Term After Stopping Imatinib (STIM 2)

Chronic Myeloid Leukaemia

France
Kerman University of Medical Sciences

Terminated

Population Pharmacokinetics of Imatinib in CML Patients in Iran

Chronic Myelogenous Leukemia

Iran, Islamic Republic of
Novartis

Completed

Effect of Food on Bioavailability of Modified Release Formulations of Imatinib

Healthy
Assistance Publique Hopitaux De Marseille

Unknown

Efficacy of Imatinib in Patients With Intermediate-risk Gastrointestinal Stromal Tumor With a High-risk Genomic Grade Index (GIGIST)

Gastrointestinal Stromal Tumor
Novartis Pharmaceuticals

Terminated

Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH) (IMPRES Extn)

Pulmonary Arterial Hypertension

Spain, Germany, Belgium, Switzerland, United States, Netherlands, Austria, Canada, Korea, Republic of, Italy, Japan, United Kingdom, France
Novartis Pharmaceuticals

Terminated

Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension

Germany, Belgium, United Kingdom, United States, Lithuania, Italy, Australia

Search clinical trials for: Icotinib Hydrochloride

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Armenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations